Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine erlotinib and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

摘要

PurposeTargeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to impact its natural history. We tested the hypothesis that simulataneous targeting of the EGFR and IGF-1R pathways would significantly improve progression free survival (PFS) by abrogating reciprocal signaling that promote drug resistance.